A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

CompletedOBSERVATIONAL
Enrollment

274

Participants

Timeline

Start Date

April 12, 2020

Primary Completion Date

March 4, 2021

Study Completion Date

May 12, 2021

Conditions
BRAF V600E Mutation PositiveMetastatic Colorectal Cancer
Interventions
OTHER

Non Interventional study

Non Interventional study

Trial Locations (34)

Unknown

Barmherzige Brüder Krankenhaus St. Veit/Glan., Saint Veit/Glan

Medizinische Universität Wien, Vienna

Imelda VZW, Bonheiden

AZ Klina, Brasschaat

UZ Leuven, Leuven

CHC MontLégia, Liège

CHRU de Besançon, Besançon

GHPSO (Groupe Hospitalier Sud de l'Oise), Creil

CHU Grenoble Alpes, La Tronche

Hôpital Franco-Britannique, Levallois-Perret

Centre Oscar Lambert, Lille

ICM Val d'Aurelle, Montpellier

CHU de Poitiers, Poitiers

Gustave Roussy, Villejuif

Klinikum Aschaffenburg Medical Klinik IV, Aschaffenburg

Studienzentrale Gokos, Dresden

Universitätsklinikum Essen, Essen

Facharztzentrum Eppendorf, Hamburg

Oncoresearch Lerchenfeld, Hamburg

MVZ Mitte Leipzig, Leipzig

MZ Onkologie Velbert/Ratingen/Mettmann, Velbert

Clinica Oncologica Ospedali Riuniti di Ancona, Ancona

Santa Maria Goretti Hospital, Latina

Instituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli

Azienda Ospedaliero-Universitaria Pisana, Pisa

AUSL-IRCCS of Reggio Emilia-Clinical Cancer Center, Reggio Emilia

Asst Valle Olona, Saronno

Hospital del Mar, Barcelona

La Paz University Hospital, Madrid

Hospital General Universitario de Valencia, Valencia

University Hospitals Birmingham NHS Foundation Trust, Birmingham

Harrogate & District NHS Foundation Trust, Harrogate

Imperial College Healthcare NHS Trust, London

University College London Hospitals NHS Foundation Trust, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Clinact

OTHER

lead

Pierre Fabre Medicament

INDUSTRY

NCT04317599 - A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | Biotech Hunter | Biotech Hunter